Real world data on QTc prolongation with osimertinib

Stephen V Liu shared on X:

“Real world data on QTc prolongation with osimertinib. 970 pts with EGFR NSCLC and pre/post EKGs: 0.9% had G3 QTc prolongation (median onset d49) with no arrhythmic events; most had baseline QTc>450. Rechallenge better with dose reduction.”

Read further.
Source: Stephen V Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.